Table 1.
Demographics of patients without irAE and with irAE
| Total | Frequency (%) |
|||
|---|---|---|---|---|
| (n = 168) | without irAE (n = 71) (42.3) | with irAE (n = 97) (57.7) | p value | |
| Age | ||||
| Mean (SD) | 67 (11.0) | 65 (11.3) | 69 (10.6) | |
| Median (IQR) | 69 (60, 75) | 66 (57, 73) | 71 (63, 76) | 0.004# |
| Range | 25–88 | 33–88 | 25–85 | |
| Gender | ||||
| Male | 144 (85.7) | 56 (78.9) | 88 (90.7) | 0.030 |
| Female | 24 (14.3) | 15 (21.1) | 9 (9.3) | |
| Ethnicity | ||||
| Chinese | 114 (67.9) | 48 (67.6) | 66 (68.0) | |
| Malay | 10 (6.0) | 3 (4.2) | 7 (7.2) | |
| Indian | 4 (2.4) | 1 (1.4) | 3 (3.1) | 0.487^ |
| Caucasian | 2 (1.2) | 2 (2.8) | 0 (0.0) | |
| Others | 38 (22.6) | 17 (23.9) | 21 (21.6) | |
| BMI | ||||
| Mean (SD) | 24 (4.1) | 25 (4.0) | 24 (4.2) | |
| Median (IQR) | 24 (22, 26) | 24 (22, 27) | 24 (22, 26) | 0.510# |
| Range | 15–39 | 17–36 | 15–39 | |
| BMI | ||||
| BMI <23 | 64 (38.1) | 25 (35.2) | 39 (40.2) | 0 602^ |
| BMI >23 | 101 (60.1) | 44 (62.0) | 57 (58.8) | (0.568) |
| Unknown | 3 (1.8) | 2 (2.8) | 1 (1.0) | |
| ECOG status | ||||
| ECOG 0 | 102 (60.7) | 38 (53.5) | 64 (66.0) | |
| ECOG 1 | 59 (35.1) | 27 (38.0) | 32 (33.0) | 0.037^ |
| ECOG 2/3 | 7 (4.2) | 6 (8.5) | 1 (1.0) | |
| BCLC staging | ||||
| B | 28 (16.7) | 8 (11.3) | 20 (20.6) | 0.108 |
| C | 140 (83.3) | 63 (88.7) | 77 (79.4) | |
| Extrahepatic mets | ||||
| No | 58 (34.5) | 19 (26.8) | 39 (40.2) | 0.070 |
| Yes | 110 (65.5) | 52 (73.2) | 58 (59.8) | |
| Macrovascular invasion | ||||
| No | 84 (50.0) | 34 (47.9) | 50 (51.5) | 0.639 |
| Yes | 84 (50.0) | 37 (52.1) | 47 (48.5) | |
| Child-Pugh score | ||||
| 5 or 6 | 131 (78.0) | 51 (71.8) | 80 (82.5) | |
| 7 | 23 (13.7) | 11 (15.5) | 12 (12.4) | 0.160 |
| 8 or 9 | 14 (8.3) | 9 (12.7) | 5 (5.2) | |
| ALBI grade | ||||
| ≤-2.60 | 34 (20.2) | 10 (14.1) | 24 (24.7) | |
| >-2.6 to ≤–1.39 | 119 (70.8) | 53 (74.6) | 66 (68.0) | 0.282^ |
| >-1.39 | 13 (7.7) | 7 (9.9) | 6 (6.2) | (0.195) |
| Unknown | 2 (1.2) | 1 (1.4) | 1 (1.0) | |
| AFP | ||||
| <400 μg/L | 91 (54.2) | 33 (46.5) | 58 (59.8) | 0.099^ |
| ≥400 μg/L | 76 (45.2) | 38 (53.5) | 38 (39.2) | (0.074) |
| Unknown | 1 (0.6) | 0 (0.0) | 1 (1.0) | |
| Etiology | ||||
| Hepatitis B | 97 (57.7) | 48 (67.6) | 49 (50.5) | |
| Hepatitis C | 15 (8.9) | 1 (1.4) | 14 (14.4) | 0.007 |
| Nonviral | 56 (33.3) | 22 (31.0) | 34 (35.1) | |
| Immunotherapy regimen | ||||
| IO Monotherapy | 139 (82.7) | 61 (85.9) | 78 (80.4) | |
| IO-IO Combination | 16 (9.5) | 5 (7.0) | 11 (11.3) | 0.600 |
| IO-TKI/mAb combination | 13 (7.7) | 5 (7.0) | 8 (8.2) | |
| Immunotherapy | ||||
| Monotherapy | 139 (82.7) | 61 (85.9) | 78 (80.4) | 0.351 |
| Combination | 29 (17.3) | 10 (14.1) | 19 (19.6) | |
| Immunotherapy (line of therapy) | ||||
| First line | 114 (67.9) | 48 (67.6) | 66 (68.0) | |
| Second line | 44 (26.2) | 18 (25.4) | 26 (26.8) | 0.863^ |
| Third line | 9 (5.4) | 4 (5.6) | 5 (5.2) | |
| Fourth line | 1 (0.6) | 1 (1.4) | 0 (0.0) | |
p value estimated using χ2 test unless otherwise stated. p value within parenthesis excludes the category “unknown/NA.” irAE, immune-related adverse event; SD, standard deviation; IQR, interquartile range.
#
p value estimated using Mann-Whitney U test.
^
p value estimated using Fisher's exact test.